<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-100468" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Trisomy 13</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Noriega</surname>
            <given-names>Marco A.</given-names>
          </name>
          <aff>Universidad Aut&#x000f3;noma de Guadalajara</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddik</surname>
            <given-names>Abu Bakar</given-names>
          </name>
          <aff>Northern International Medical College &#x00026; Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Noriega declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abu Bakar Siddik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-100468.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Trisomy 13 is a chromosomal aneuploidy characterized by meiotic nondisjunction. The phenotypic holoprosencephaly and midline fusion aberrancies are related to a defective fusion of the prechordal mesoderm. Patau syndrome has a mortality of over 95%. This activity addresses this condition and provides clinicians with the information to evaluate and manage this condition when it presents.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology and epidemiology of trisomy 13.</p></list-item><list-item><p>Review the factors relating to the prenatal diagnosis of trisomy 13.</p></list-item><list-item><p>Summarize the management options available for trisomy 13.</p></list-item><list-item><p>Describe some interprofessional team strategies for improving care coordination and communication in the diagnosis of trisomy 13.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=100468&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=100468">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-100468.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Trisomy 13 is a chromosomal aneuploidy<bold>&#x000a0;</bold>originally described by Patau et al. in 1960.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref>&#x000a0;The occurrence of trisomy 13 is 1 in 10,000&#x000a0;to 20,000 live births with antenatal mortality of over 95% of gestations.<xref ref-type="bibr" rid="article-100468.r2">[2]</xref><xref ref-type="bibr" rid="article-100468.r3">[3]</xref>&#x000a0;It can occur as complete, partial, or mosaic expression.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref>&#x000a0;The complete trisomy is the most common presentation representing about 80% of all patients. This expression characteristically demonstrates the presence of three chromosomes 13 copies.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref>&#x000a0;The partial expression is characterized by a Robertsonian translocation t(13;14),&#x000a0;while only 5% of all cases present with mosaicism.<xref ref-type="bibr" rid="article-100468.r4">[4]</xref>&#x000a0;Mosaicism is characterized by a percentage of cells remaining trisomic while others maintain euploidy.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref>&#x000a0;</p>
        <p>Trisomy 13 arises from the nondisjunction of germ cells during meiosis I or II of either parental cells.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref> Nonetheless, maternal germ cell nondisjunction correlated to the increased age of conception contributes to 91% of cases.<xref ref-type="bibr" rid="article-100468.r3">[3]</xref>&#x000a0;The mode of inheritance for the complete trisomy 13 is caused by spontaneous interference in meiosis, while vertical inheritance is hereditary in balanced translocations.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref>&#x000a0;</p>
        <p>Phenotypic findings in trisomy 13 are associated with patterns of congenital anomalies and mental disabilities incompatible with life.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref> The embryological defects in trisomy 13 develop in the absence of fusion of prechordal mesoderm, which phenotypically presents as midline defects. These midline defects are associated with aberrant SHH genes.<xref ref-type="bibr" rid="article-100468.r6">[6]</xref>&#x000a0;Despite the accelerated mortality of trisomy 13, it remains clinically significant due to its variable expressivity in patients with compatible mosaicisms.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref>&#x000a0; &#x000a0; &#x000a0;</p>
      </sec>
      <sec id="article-100468.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Trisomy 13 results from the nondisjunction of homologous chromosomes during gametogenesis, characterized by three copies of chromosome 13 in somatic and germ cell lines.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref>&#x000a0;Maternal nondisjunction represents 91% of cases typically due to errors in meiosis I. Meiotic errors originate from the aberrant recombination of chromosomes, which has a greater incidence among conceptions in women older than 35 years of age.<xref ref-type="bibr" rid="article-100468.r3">[3]</xref>&#x000a0;</p>
        <p>A less phenotypically challenging trisomy can occur in a translocation. These translocations originate from two acrocentric breaks in the juxtacentromeric regions (usually chromosomes 13 and 14). The phenotypic expression will depend on the balance of the translocation. Balanced Robertsonian translocations will be less severe than those with an altered genetic quantity, as seen in unbalanced translocations.<xref ref-type="bibr" rid="article-100468.r7">[7]</xref>&#x000a0;The mosaic form of trisomy 13 occurs when some cell lines have the extra chromosomal material.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref>&#x000a0;Mosaicism phenotype presents with varied expressivity with an increased intellectual sparing.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref></p>
      </sec>
      <sec id="article-100468.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Trisomy 13 is the third most common trisomy, occurring in 1 in 10,000&#x000a0;to 20,000 live births.&#x000a0;The antenatal mortality represents the majority of deaths, with a postnatal survival rate of 6&#x000a0;to 12% beyond the first year of life.<xref ref-type="bibr" rid="article-100468.r2">[2]</xref>&#x000a0;About 90% of trisomy 13 diagnoses made in developed countries are antenatal.<xref ref-type="bibr" rid="article-100468.r8">[8]</xref>&#x000a0;Cardiac and nervous system anomalies are amongst the most common malformations in trisomy 13.<xref ref-type="bibr" rid="article-100468.r9">[9]</xref></p>
      </sec>
      <sec id="article-100468.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The meiotic nondisjunction in trisomy 13 causes a series of genetic aberrancies related to defects in prechordal mesoderm fusion.<xref ref-type="bibr" rid="article-100468.r6">[6]</xref>&#x000a0;The faulty fusion causes midline defects, which develop into phenotypic malformations incompatible with life. Some specific genetic mapping has identified a vast array of tumors in trisomy 13 carriers.<xref ref-type="bibr" rid="article-100468.r2">[2]</xref></p>
      </sec>
      <sec id="article-100468.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The anatomic-histological classification of trisomy 13 was described in 1966 by Snodgrass et al. as two categories based on the presence or absence of holoprosencephaly.<xref ref-type="bibr" rid="article-100468.r10">[10]</xref>&#x000a0;Further evaluation of the external phenotype is commonly presented with postaxial hexadactyly. Midline malformations of internal organs are frequent, which include septal cardiac defects and M&#x000fc;llerian defects such as uterus didelphys.<xref ref-type="bibr" rid="article-100468.r10">[10]</xref>&#x000a0;The microscopic examination of aborted fetuses with trisomy 13 presents abnormal metanephric differentiation with the persistence of embryologic structures. Most of the embryologic malformations are traceable to mesoderm migration via the presence of olfactory aplasia since normal morphogenic development of craniofacial and forebrain structures occurs in the third week of embryogenesis.<xref ref-type="bibr" rid="article-100468.r10">[10]</xref></p>
      </sec>
      <sec id="article-100468.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The typical findings in trisomy 13 include holoprosencephaly, Dandy-Walker malformation, aplasia cutis, cleft lip-palate, postaxial polydactyly, congenital heart disease, polycystic kidney disease, urogenital anomalies, and gynecological dysgenesis.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref><xref ref-type="bibr" rid="article-100468.r10">[10]</xref>&#x000a0;Internal systems can also be compromised with hyperinsulinism portrayed by persistent hypoglycemia. While in utero, the most common findings are related to growth delay.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref></p>
      </sec>
      <sec id="article-100468.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The initial evaluation of trisomy 13 starts with fetal nuchal translucency (FNT) which, is done in weeks 11&#x000a0;to 14 of gestation. As with other trisomies, the measurement typically appears greater or equal to 3.5mm.<xref ref-type="bibr" rid="article-100468.r11">[11]</xref>&#x000a0;Part of the first-trimester screening also includes the measurement of free beta subunit or total human chorionic gonadotropin (B-hCG) and pregnancy-associated plasma protein-A (PAPP-A). During the first trimester, both biomarkers appear decreased, making it undifferentiated from trisomy 18 screening.<xref ref-type="bibr" rid="article-100468.r11">[11]</xref>&#x000a0;</p>
        <p>Non-invasive prenatal testing (NIPT ) is possible using cell-free DNA in maternal plasma to differentiate trisomy 18 and 21 from 13; nonetheless, cost per value continues to support the use of invasive techniques.<xref ref-type="bibr" rid="article-100468.r12">[12]</xref>&#x000a0;Chorionic villus sampling (CVS) can be performed in an early window between gestational weeks 11 and 13, while amniocentesis is generally performed in weeks 15&#x000a0;to 18.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref>&#x000a0;Recent studies suggest that the high mortality associated with trisomies 13 and 18 relate to the termination of pregnancies in up to 55% of gestations with a confirmed diagnosis.<xref ref-type="bibr" rid="article-100468.r13">[13]</xref>&#x000a0;Nonetheless, a definite diagnosis is only achievable from a postnatal karyotype and fluorescence in situ hybridization (FISH) techniques.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-100468.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Historical evidence suggested that the syndromic presence of multiple organ dysfunctions in trisomy 13 and 18 were incompatible with life. Nonetheless, the growing communication in society has portrayed anecdotal evidence of survivors from these conditions leading guidelines and decision making into a moral gray zone.<xref ref-type="bibr" rid="article-100468.r14">[14]</xref>&#x000a0;</p>
        <p>The current approach focuses on creating a communicative relationship between the parents and physicians informing them about the quality of life and the treatment options specific to their child's abnormalities.<xref ref-type="bibr" rid="article-100468.r15">[15]</xref>&#x000a0;Although surgical techniques exist for the majority of lethal malformations associated with trisomy 13, the ten-year survival post-intervention remains low at 12.9%.<xref ref-type="bibr" rid="article-100468.r16">[16]</xref></p>
      </sec>
      <sec id="article-100468.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of trisomy 13 should include Edwards syndrome due to its similarities during the initial gestational screening.<xref ref-type="bibr" rid="article-100468.r11">[11]</xref>&#x000a0;Other diagnoses should include partial duplication of 13q and pseudotrisomy 13.<xref ref-type="bibr" rid="article-100468.r17">[17]</xref>&#x000a0;The use of modern non-invasive techniques facilitates the differential diagnosis of pathologies usually prenatally associated with the same characteristics of trisomy 13.<xref ref-type="bibr" rid="article-100468.r12">[12]</xref></p>
      </sec>
      <sec id="article-100468.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Evidence suggests that postnatal mortality is approximately 50% during the first month and up to 90% during the first year.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref>&#x000a0;Recent information provided by organizations such as the support organization for Trisomy 13, 18, and related disorders (SOFT) has allowed the direct intervention of patients rather than palliative care.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref> These measures have impacted the survival rate of patients; nonetheless, there is a lack of study data to support the benefit of aggressive intervention and global survival rate.</p>
      </sec>
      <sec id="article-100468.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Maternal complications are associated with trisomy 13, concurring in an increase in mortality for both the mother and the fetus. Data suggest that a trisomy 13 gestation is related to an increased prevalence of preeclampsia and early delivery.<xref ref-type="bibr" rid="article-100468.r18">[18]</xref>&#x000a0;Nevertheless, neonatal mortality is associated with central apnea, structural cardiac incompatibilities, pulmonary hypertension, aspiration, and upper respiratory tract obstructions.<xref ref-type="bibr" rid="article-100468.r5">[5]</xref></p>
      </sec>
      <sec id="article-100468.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Antenatal integration of a multidisciplinary team should merit consideration to improve outcomes on both integral maternal health and the viability of the gestation. The evaluation team should include an obstetrician, fetal concerns center nurse, genetic counselor, neonatologist, and social worker.<xref ref-type="bibr" rid="article-100468.r13">[13]</xref>&#x000a0;Educating the patient should include the mode of inheritance of the disease, the complications of choosing to continue to pregnancy, and the value associated interventions of postnatal care.</p>
      </sec>
      <sec id="article-100468.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Trisomy 13 is the third most common nondisjunction meiotic triploidy followed by Edwards and Down syndrome.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref> The three genetic presentations are complete nondisjunction trisomy 13, a Robertsonian translocation, and mosaicism. The most common cause of holoprosencephaly is related to trisomy 13.<xref ref-type="bibr" rid="article-100468.r1">[1]</xref> During the first-trimester screening of trisomy 13, FNT will appear equal or greater than 3.5mm, with a decreased B-hCG, and PAPP-A.<xref ref-type="bibr" rid="article-100468.r11">[11]</xref>&#x000a0;Most gestations with trisomy 13 are terminated, the continuation of pregnancy increases the risk of preeclampsia.<xref ref-type="bibr" rid="article-100468.r18">[18]</xref></p>
      </sec>
      <sec id="article-100468.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nondisjunction defects during miosis are related to increased maternal age, especially those above 35 years. Evidence suggests that maternal history of a previous trisomy increases the risk of a subsequent one.<xref ref-type="bibr" rid="article-100468.r19">[19]</xref>&#x000a0;Prenatal counseling is associated with a decrease in the intensive treatment approach, increasing palliative care options for the neonate.<xref ref-type="bibr" rid="article-100468.r13">[13]</xref></p>
      </sec>
      <sec id="article-100468.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=100468&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=100468">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/trisomy-13/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=100468">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/100468/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=100468">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-100468.s17">
        <title>References</title>
        <ref id="article-100468.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cammarata-Scalisi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Araque</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ram&#x000ed;rez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guaran</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Trisomy 13 mosaicism.</article-title>
            <source>Bol Med Hosp Infant Mex</source>
            <year>2019</year>
            <volume>76</volume>
            <issue>5</issue>
            <fpage>246</fpage>
            <page-range>246-250</page-range>
            <pub-id pub-id-type="pmid">31536039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satg&#x000e9;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sirvent</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vekemans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chenard</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A tumor profile in Patau syndrome (trisomy 13).</article-title>
            <source>Am J Med Genet A</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>173</volume>
            <issue>8</issue>
            <fpage>2088</fpage>
            <page-range>2088-2096</page-range>
            <pub-id pub-id-type="pmid">28544599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Judis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shirley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Surti</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hoffner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cockwell</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hassold</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The origin of trisomy 13.</article-title>
            <source>Am J Med Genet A</source>
            <year>2007</year>
            <month>Oct</month>
            <day>01</day>
            <volume>143A</volume>
            <issue>19</issue>
            <fpage>2242</fpage>
            <page-range>2242-8</page-range>
            <pub-id pub-id-type="pmid">17853475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miryounesi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diantpour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Motevaseli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghafouri-Fard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Homozygosity for a Robertsonian Translocation (13q;14q) in a Phenotypically Normal 44, XX Female with a History of Recurrent Abortion and a Normal Pregnancy Outcome.</article-title>
            <source>J Reprod Infertil</source>
            <year>2016</year>
            <season>Jul-Sep</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>184</fpage>
            <page-range>184-7</page-range>
            <pub-id pub-id-type="pmid">27478773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macias</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Trisomy 13: Changing Perspectives.</article-title>
            <source>Neonatal Netw</source>
            <year>2016</year>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-6</page-range>
            <pub-id pub-id-type="pmid">26842537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kruszka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Muenke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Syndromes associated with holoprosencephaly.</article-title>
            <source>Am J Med Genet C Semin Med Genet</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>178</volume>
            <issue>2</issue>
            <fpage>229</fpage>
            <page-range>229-237</page-range>
            <pub-id pub-id-type="pmid">29770994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laudat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seridi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Burc-Struxiano</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Trisomy 13 by robertsonian translocation rob (13;13)(q10;q10) +13: about one case.</article-title>
            <source>Ann Biol Clin (Paris)</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>695</fpage>
            <page-range>695-698</page-range>
            <pub-id pub-id-type="pmid">29043983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Springett</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Antenatal detection of Edwards (Trisomy 18) and Patau (Trisomy 13) syndrome: England and Wales 2005-2012.</article-title>
            <source>J Med Screen</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>113</fpage>
            <page-range>113-9</page-range>
            <pub-id pub-id-type="pmid">24993362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Springett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wellesley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greenlees</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Addor</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Arriola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cavero-Carbonell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Csaky-Szunyogh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Draper</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Garne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gatt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haeusler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khoshnood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Klungsoyr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McDonnell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nelen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>O'Mahony</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Queisser-Luft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rankin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rissmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rounding</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stoianova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tuckerz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zymak-Zakutnia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Congenital anomalies associated with trisomy 18 or trisomy 13: A registry-based study in 16 European countries, 2000-2011.</article-title>
            <source>Am J Med Genet A</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>167A</volume>
            <issue>12</issue>
            <fpage>3062</fpage>
            <page-range>3062-9</page-range>
            <pub-id pub-id-type="pmid">26347425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moerman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fryns</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>van der Steen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kleczkowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lauweryns</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The pathology of trisomy 13 syndrome. A study of 12 cases.</article-title>
            <source>Hum Genet</source>
            <year>1988</year>
            <month>Dec</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>349</fpage>
            <page-range>349-56</page-range>
            <pub-id pub-id-type="pmid">3198112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rink</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Screening for fetal aneuploidy.</article-title>
            <source>Semin Perinatol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-43</page-range>
            <pub-id pub-id-type="pmid">26725144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cuckle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pergament</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Non-invasive prenatal testing for aneuploidy: current status and future prospects.</article-title>
            <source>Ultrasound Obstet Gynecol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-33</page-range>
            <pub-id pub-id-type="pmid">23765643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leuthner</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prenatal counseling and parental decision-making following a fetal diagnosis of trisomy 13 or 18.</article-title>
            <source>J Perinatol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>788</fpage>
            <page-range>788-796</page-range>
            <pub-id pub-id-type="pmid">29740195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lantos</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Trisomy 13 and 18--Treatment Decisions in a Stable Gray Zone.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jul</month>
            <day>26</day>
            <volume>316</volume>
            <issue>4</issue>
            <fpage>396</fpage>
            <page-range>396-8</page-range>
            <pub-id pub-id-type="pmid">27458943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallotto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lantos</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Treatment Decisions for Babies with Trisomy 13 and 18.</article-title>
            <source>HEC Forum</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-222</page-range>
            <pub-id pub-id-type="pmid">28365826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Rosella</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Mahant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guttmann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Survival and Surgical Interventions for Children With Trisomy 13 and 18.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jul</month>
            <day>26</day>
            <volume>316</volume>
            <issue>4</issue>
            <fpage>420</fpage>
            <page-range>420-8</page-range>
            <pub-id pub-id-type="pmid">27458947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wyllie</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Natural history of trisomy 13.</article-title>
            <source>Arch Dis Child</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>343</fpage>
            <page-range>343-5</page-range>
            <pub-id pub-id-type="pmid">7979530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dotters-Katz</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Senz</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Shaffer</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Kuller</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Caughey</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Trisomy 13 and the risk of gestational hypertensive disorders: a population-based study.</article-title>
            <source>J Matern Fetal Neonatal Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>15</issue>
            <fpage>1951</fpage>
            <page-range>1951-1955</page-range>
            <pub-id pub-id-type="pmid">28514881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-100468.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Souza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Recurrence risks for trisomies 13, 18, and 21.</article-title>
            <source>Am J Med Genet A</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>149A</volume>
            <issue>12</issue>
            <fpage>2716</fpage>
            <page-range>2716-22</page-range>
            <pub-id pub-id-type="pmid">19921649</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
